Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

The price target boosts come after LLY stock rose 30% during November amid a strong rally in the shares. The bull run comes ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

The average one-year price target for Eli Lilly and (NYSE:LLY) has been revised to $1,020.92 / share. This is an increase of 10.15% from the prior estimate of $926.82 dated November 7, 2025. The price ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue.

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new ...